Immuneering’s (IMRX) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research note released on Wednesday,Benzinga reports. Chardan Capital currently has a $13.00 price target on the stock.

Separately, Needham & Company LLC restated a “buy” rating and set a $15.00 price target on shares of Immuneering in a research note on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $12.80.

Immuneering Stock Down 0.5 %

IMRX stock opened at $2.10 on Wednesday. The company has a market cap of $65.21 million, a price-to-earnings ratio of -1.07 and a beta of -0.40. The business has a fifty day simple moving average of $2.22 and a 200-day simple moving average of $1.63. Immuneering has a 52 week low of $1.00 and a 52 week high of $8.89.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Vontobel Holding Ltd. acquired a new position in Immuneering in the 3rd quarter worth $25,000. Corsair Capital Management L.P. acquired a new position in Immuneering in the third quarter worth about $25,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Immuneering in the second quarter valued at about $44,000. XTX Topco Ltd raised its stake in Immuneering by 37.3% during the second quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after buying an additional 9,274 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in Immuneering during the 2nd quarter worth approximately $67,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.